Synopsis
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
À propos des auteurs
Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
Zhe-Sheng Chen opened the St. John's University's first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen serves as Editor of "African Journal of Pharmacy and Pharmacology"; Editor-in-Chief of "Journal of Cancer Research Updates" and "Journal of New Developments in Chemistry". He also serves as an Editorial Board member of 25 journals, an Ad Hoc reviewer of 180 journals, and a guest editor of "Current Pharmaceutical Biotechnology", "Cancer" and "Journal of International Medical Research". Chen has over 170 papers published, 6 book chapters, and 5 patents.
Dong-Hua Yang is an Assistant Professor at St. John's University College of Pharmacy and Health Sciences. She works in the fields of Cancer Biomarkers and Cancer Pharmacology. Before joining St. John's, she was a Research Assistant Professor at Fox Chase Cancer Center, where she took charge of the Tissue Research Service at the Biosample Repository Core Facility. She is a leading expert in the field of immunohistochemistry (IHC) and IHC quantitative analysis. She applied IHC technology to study the molecular alterations of known and novel signaling pathways that regulate embryogenesis, organ morphogenesis and tumorigenesis. Yang leads the automatic quantitative analysis (AQUA) for immunohistochemistry and immunofluorescence assays for biomarker research. Yang is the regional editor of "Current Proteomics", guest editor of "Frontiers of Pharmacology", "Cancers" and "Molecules", associate editor of " Journal of Nutritional Therapeutics", "Journal of Cancer Research Updates" and "Journal of Analytical Oncology", ad hoc reviewer of 0ver 50 journals. Yang has over 70 papers and 4 book chapters published.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Autres éditions populaires du même titre
Résultats de recherche pour Protein Kinase Inhibitors As Sensitizing Agents for...
Image fournie par le vendeur
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy (Cancer Sensitizing Agents for Chemotherapy, Volume 4)
Edité par
Academic Press, 2019
ISBN 10 : 0128164352
ISBN 13 : 9780128164358
Ancien ou d'occasion
Couverture rigide
Edition originale
Vendeur : killarneybooks, Inagh, CLARE, Irlande
Évaluation du vendeur 5 sur 5 étoiles
Hardcover. Etat : Good. 1st Edition. Good+. Oversized hardcover, xxi + 270 pages, NOT ex-library. A corner crease to a portion of leaves. Interior is clean and bright throughout with unmarked text, free of inscriptions and stamps, firmly bound. Boards show rubbing and short creases to corners. Issued without a dust jacket. -- The book focuses on the use of protein kinase inhibitors (PKIs) to overcome multidrug resistance (MDR) in cancer treatment. Drawing from experimental and clinical research, it documents the biochemical, genetic, and molecular mechanisms by which PKIs sensitize tumors to chemotherapeutic agents. It offers 15 detailed review chapters, each addressing a distinct molecular target or signaling pathway, with implications for both solid and hematologic malignancies. The work serves as a reference for cancer researchers, oncologists, and clinicians designing or evaluating combinatory treatment strategies in the context of MDR. The introductory framework outlines the rationale for combining kinase inhibitors with chemotherapy. Resistance mechanisms - ranging from altered signal transduction to enhanced drug efflux via ATP-binding cassette (ABC) transporters - are central to treatment failure. The editors present kinase inhibitors as modulators that can reverse such resistance by targeting dysregulated pathways, thereby enhancing chemosensitivity and lowering effective drug doses. Chapters 1 through 4 focus on well-characterized tyrosine kinase pathways, beginning with EGFR and HER2, whose inhibitors (e.g., gefitinib, osimertinib) restore chemosensitivity in tumors with high ABC transporter activity. BCR-ABL inhibitors, such as imatinib, are examined for their dual role in chronic myeloid leukemia (CML) treatment and their regulatory effect on transporter expression. The VEGF/VEGFR axis and its blockade (e.g., with bevacizumab) is considered from an antiangiogenic perspective, while ALK inhibitors are reviewed for their ability to resensitize tumor cells through transporter modulation. Chapters 5-10 broaden the scope to include STAT3, FLT3, BTK, CDKs, and Bcl-2 - targets implicated in apoptosis evasion, aberrant cell cycling, and survival signaling. STAT3, though not yet clinically inhibited, is presented as a key future target due to its central role in oncogenesis. FLT3 inhibitors (e.g., midostaurin) are explored in acute myeloid leukemia, with attention to their impact on drug uptake and blood-brain barrier permeability. BTK inhibitors, particularly ibrutinib, are analyzed for their combination potential in hematologic malignancies. CDK inhibitors (e.g., palbociclib) and Bcl-2 antagonists are detailed in relation to phase-specific chemosensitization and apoptosis restoration. Chapters 11 to 15 cover kinase-related mechanisms and lesser-studied inhibitors, including Plk1, BRAF, and JAK modulators, which indirectly affect drug resistance via ABC transporter interactions. The PI3K/Akt pathway is reviewed in two chapters: first as a general resistance driver and target for sensitization, then in the broader context of mTOR and IGF signaling. These sections present the rationale for dual inhibition and review several trials combining these agents with cytotoxic therapies. The final chapter addresses MDM2/p53 interactions and their inhibition as a route to restoring tumor suppressor function, particularly in cancers with intact but suppressed p53 activity. Emphasis is placed throughout on mechanistic understanding as a prerequisite for therapeutic intervention. Each chapter includes summaries of preclinical data, clinical trials where available, and potential off-target effects. The book provides a modular yet comprehensive reference for designing synergistic cancer therapies involving kinase-targeted agents. It consolidates current targets and inhibitors with translational potential and contextualizes emerging therapies within molecular resistance frameworks to support evidence-based treatment decisions. N° de réf. du vendeur 011352
Acheter D'occasion
EUR 65,50
Expédition à EUR 34,84
Expédition depuis Irlande vers Etats-Unis
Expédition depuis Irlande vers Etats-Unis
Quantité disponible : 1 disponible(s)
Image d'archives
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy: Volume 4
impression à la demandeVendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Évaluation du vendeur 4 sur 5 étoiles
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur 423d3e80d92570871b63dab5f4f6ec93
Acheter neuf
EUR 138,55
Expédition à EUR 8
Expédition depuis Italie vers Etats-Unis
Expédition depuis Italie vers Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image d'archives
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy (Volume 4) (Cancer Sensitizing Agents for Chemotherapy (Volume 4))
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Évaluation du vendeur 4 sur 5 étoiles
Etat : New. N° de réf. du vendeur 379016117
Acheter neuf
EUR 156,42
Expédition à EUR 7,45
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : 3 disponible(s)
Image d'archives
Protein Kinase Inhibitors As Sensitizing Agents for Chemotherapy
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Hardcover. Etat : Brand New. 300 pages. 9.25x7.50x0.94 inches. In Stock. N° de réf. du vendeur __0128164352
Acheter neuf
EUR 157,11
Expédition à EUR 11,47
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : 2 disponible(s)
Image fournie par le vendeur
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Edité par
Elsevier Science Nov 2018, 2018
ISBN 10 : 0128164352
ISBN 13 : 9780128164358
Neuf
Couverture rigide
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. 292 pp. Englisch. N° de réf. du vendeur 9780128164358
Acheter neuf
EUR 150
Expédition à EUR 23
Expédition depuis Allemagne vers Etats-Unis
Expédition depuis Allemagne vers Etats-Unis
Quantité disponible : 2 disponible(s)
Image d'archives
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy (Volume 4) (Cancer Sensitizing Agents for Chemotherapy (Volume 4))
Vendeur : Books Puddle, New York, NY, Etats-Unis
Évaluation du vendeur 4 sur 5 étoiles
Etat : New. N° de réf. du vendeur 26383839338
Acheter neuf
EUR 171,93
Expédition à EUR 3,43
Expédition nationale : Etats-Unis
Expédition nationale : Etats-Unis
Quantité disponible : 3 disponible(s)
Image d'archives
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy (Volume 4) (Cancer Sensitizing Agents for Chemotherapy (Volume 4))
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Évaluation du vendeur 4 sur 5 étoiles
Etat : New. N° de réf. du vendeur 18383839328
Acheter neuf
EUR 174,31
Expédition à EUR 9,95
Expédition depuis Allemagne vers Etats-Unis
Expédition depuis Allemagne vers Etats-Unis
Quantité disponible : 3 disponible(s)
Image d'archives
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy: Volume 4
Edité par
Elsevier Science Publishing Co Inc, 2018
ISBN 10 : 0128164352
ISBN 13 : 9780128164358
Neuf
Couverture rigide
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Hardback. Etat : New. New copy - Usually dispatched within 4 working days. N° de réf. du vendeur B9780128164358
Acheter neuf
EUR 172,66
Expédition à EUR 21,91
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image fournie par le vendeur
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy : Volume 4
Edité par
Elsevier Science, 2018
ISBN 10 : 0128164352
ISBN 13 : 9780128164358
Neuf
Couverture rigide
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. N° de réf. du vendeur 9780128164358
Acheter neuf
EUR 165,99
Expédition à EUR 63,85
Expédition depuis Allemagne vers Etats-Unis
Expédition depuis Allemagne vers Etats-Unis
Quantité disponible : 2 disponible(s)